Seminars in Hematology
Volume 44, Issue 4 , Pages 286-295 , October 2007

High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults

  • Paolo Pedrazzoli

      Affiliations

    • Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca’ Granda, Milano, Italy.
    • ,
  • Giovanni Rosti

      Affiliations

    • Oncologia Medica, Ospedale Regionale, Treviso, Italy.
    • ,
  • Simona Secondino

      Affiliations

    • Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca’ Granda, Milano, Italy.
    • ,
  • Ornella Carminati

      Affiliations

    • Department of Oncology, Forli, Italy.
    • ,
  • Taner Demirer

      Affiliations

    • Department of Hematology, Ankara University Medical School, Ibni Sina Hospital, Ankara, Turkey.
    • Corresponding Author InformationAddress correspondence to Taner Demirer, MD, FACP, Department of Hematology/Oncology, Ankara University Medical School, Cebeci Hospital, Ankara, Turkey.
    • ,
  • European Group for Blood and Marrow Transplantation
    • ,
  • Solid Tumors Working Party
    • ,
  • Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare

References 

  1. Skipper HE. Dose intensity versus total dose of chemotherapy: An experimental basis. In:  De Vita VT,  Hellman S,  Rosenberg SA editor. Important Advances in Oncology. Philadelphia, PA: Lippincott; 1990;p. 43–64
  2. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, De Giorgi U, Carminati O, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant. 2003;32:489–494
  3. Eder J, Antman K, Peters W, Henner WD, Elias A, Shea T, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986;4:1592–1597
  4. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132–1143
  5. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol. 1997;15:2312–2321
  6. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18:1360–1377
  7. Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Hermann AA, et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. Lancet. 2000;355:999–1003
  8. Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A. Haematopoietic stem cell transplantation (HSCT) in Europe 2002 (Changes in indication and impact of team density. A report of the EBMT activity survey). Bone Marrow Transplant. 2004;34:855–875
  9. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: Follow-up at 12 years. Cancer. 2006;106:2327–2336
  10. Schrama JG, Faneyte IF, Schronagel JH, Baars JW, Pertese JL, van de Vijver MJ, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol. 2002;13:689–698
  11. Tokuda Y, Tajima T, Narabayashi M, Takeyama T, Watanabe T, Fukutomi T, et al. Randomized phase 3 study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology (JCOG9208). Proc Am Soc Clin Oncol. 2001;20:38a;(abstr)
  12. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial (Scandinavian Breast Group 9401 study). Lancet. 2000;356:1384–1391
  13. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst. 2004;96:1076–1083
  14. Zander AR, Kroger N, Schmoor C, Kruger W, Möbus V, Frickhofen N, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol. 2004;22:2273–2283
  15. Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala , et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol. 2005;16:726–734
  16. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in high risk breast cancer. N Engl J Med. 2003;349:17–26
  17. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med. 2003;349:80–82
  18. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23:2191–2200
  19. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol. 1999;18:1a;(abstr)
  20. Roché H, Pouillard P, Meyer N, Biron P, Spielmann M, Janvier M, et al. Adjuvant high-dose improves early outcome for high-risk (N>7) breast cancer patients: The PEGASE-01 trial. Proc Am Soc Clin Oncol. 2001;20:26a;(abstr)
  21. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). Proc Am Soc Clin Oncol. 2001;20:21a;(abstr)
  22. Basser RL, O’Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006;24:370–378
  23. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006;17:588–596
  24. Nitz UA, Mohrmann S, Fisher J, Lindemann W, Berdel WE, Jackisch C, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet. 2005;366:1935–1944
  25. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  26. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 2007;18:202–203
  27. Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res. 2007;13:488–497
  28. Crump M, Glück S, Stewart D, Levine M, Pritchard K, Kirkbride P, et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: A National Cancer Institute of Canada (NCIC) clinical trials group study. (abstract) Proc Am Soc Clin Oncol. 2001;20:21a;(abstr)
  29. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer (Philadelphia Bone Marrow Transplant Group). N Engl J Med. 2000;342:1069–1076
  30. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5-year update of the ‘Philadelphia Trial’ (PBT-1). Proc Am Soc Clin Oncol. 2002;69:43a;(abstr)
  31. Biron P, Durand M, Rochè H, Delozier T, Battista C, Fargeot P, et al. High dose thiotepa, cyclophosphamide and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer (Results of the PEGASE 03 French Protocol). Proc Am Soc Clin Oncol. 2002;21:42a;(abstr)
  32. Lotz JP, Cure H, Janvier M, Asselain B, Morvan F, Legros M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: Final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer. 2005;41:71–80
  33. Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006;37:1009–1015
  34. Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant. 2006;12:195–203
  35. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23:432–440
  36. Crown J, Perey L, Lind M, Guillem V, Efremdis A, Garcia-Conde J, et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (patients) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS). Proc Am Soc Clin Oncol. 2003;22:23;(abstr)
  37. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, Mcweeney PA, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707–718
  38. Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, et al. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplantation in metastatic breast cancer results in survival benefit. Breast J. 2006;12:531–235
  39. Kroger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol. 2006;24:3919–3926
  40. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol. 2006;17:1479–1488
  41. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest. 1999;116(suppl 6):531S–538S
  42. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiles J, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung; a randomized study. J Clin Oncol. 1987;5:1864–1873
  43. Woll PJ, Thatcher N, Lomax L, Hodgetts J, Ming Lee S, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients. J Clin Oncol. 2001;19:712–719
  44. Lorigan P, Woll PJ, O’Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst. 2005;97:666–674
  45. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Aversa S, Brunsvig P, et al. High-dose sequential chemotherapy supported by peripheral blood progenitor cells for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial. Proc EBMT Bone Marrow Transplant. 2007;39:O172;(abstr)
  46. Rosti G, Carminati O, Monti M, Tamberi S, Marangolo M. Chemotherapy advances in small cell lung cancer. Ann Oncol. 2006;17(suppl 5):v99–v102
  47. Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007;25:85–90
  48. Einhorn LH, Williams SD, Chamness BA, Brames MJ, Perkins SM, Abanour R. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–348
  49. Lotz J-P, Bui P, Gomez , Théodore C, Fizazi K, et al. Refractory germ cell tumors (GCTs): Salvage high-dose chemotherapy(HD-CT) combining 2 mobilization regimes followed by 3 GD-CT with peripheral blood stem cell transplantation PBSCT: The TAXIF regimen (GETUG). Ann Oncol. 2005;16:411–418
  50. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol. 1996;14:2638–2645
  51. Rosti G, De Giorgi U, Salvioni R, Papiani G, Sebastiani M, Argnani M, et al. Salvage high-dose chemotherapy in patients with germ cell tumors: An Italian experience with 84 patients. Cancer. 2002;95:309–315
  52. Bhatia S, Abanour R, Porcu P, Shesadri R, Nichols CR, Cornetta K, et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000;18:3346–3351
  53. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol. 2005;16:1152–1159
  54. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, et al. Long-term results of the first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–4091
  55. Rosti G, De Giorgi U, Wandt H, Liure B, Leyvraz S, Kolbe K, et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: The experience of the European Group for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant. 2004;34:1033–1037
  56. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: A prospective trial. Br J Cancer. 2003;89:29–35
  57. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomised trial of conventional-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256
  58. Van Dijk MR, Steyerberg EW, Habbema DF. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer. 2006;42:820–826
  59. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997;15:1309–1317
  60. Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long term results. J Clin Oncol. 1997;15:1302–1308
  61. Lederman JA, Herd R, Maraninchi D, Viens P, Buclon M, Philip T, et al. High-dose chemotherapy for ovarian carcinoma: Long term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2001;12:639–699
  62. Stiff P, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry. Ann Intern Med. 2000;133:504–515
  63. Cure H, Battista C, Guastalla JP, Fabbro M, Tubiana N, Bourgeois H, et al. Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cells (PBSC) support as consolidation in patients (patients) with responsive low-burden advanced ovarian cancer (AOC): A 5-year follow-up of a GINECO/FNCLCC/SFGM–TC study. Proc Am Soc Clin Oncol. 2004;22:5006;(abstr)
  64. Ledrman JA, Frickhofen N, Wandt , Bengala C, Champion K, Hinke V, et al. A phase III randomised trial of sequential high dose chemotherapy (HDC) for first-line treatment of ovarian cancer. Proc Am Soc Clin Oncol. 2005;23:5006;(abstr)
  65. Hortobagyi GN. What is the role of high-dose chemotherapy in the era of targeted therapies?. J Clin Oncol. 2004;22:2263–2266
  66. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  67. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  68. Siena S. Towards the integration of hematopoietic stem cells into therapy of breast cancer?. Haematologica. 1999;84:865–867

 Supported in part by grant regionale 2005, Associazione Italiana per la Ricerca sul Cancro (AIRC) to P.P. and Oncologia Ca’ Granda ONLUS Fondazione to P.P. and S.S

PII: S0037-1963(07)00125-4

doi: 10.1053/j.seminhematol.2007.08.009

Seminars in Hematology
Volume 44, Issue 4 , Pages 286-295 , October 2007

Article Tools